PRTA
PRTA clinical trials: PROTHENA CORP PUBLIC LTD CO
Every trial on ClinicalTrials.gov where PROTHENA CORP PUBLIC LTD CO is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 13
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PRTA on the catalyst calendar · PRTA registry changes
- Primary completion Jan 16, 2026ActualPhase 1NCT06699680Phase 1 Study of PRX019 in Healthy Adult VolunteersProthena Biosciences Ltd. · Healthy Participants StudyCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2025ActualPhase 3NCT04973137A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL AmyloidosisProthena Biosciences Ltd. · Light Chain (AL) AmyloidosisTerminatedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2018ActualPhase 3NCT02312206The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL AmyloidosisProthena Biosciences Ltd. · Primary Systemic (AL) AmyloidosisTerminatedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2020ActualPhase 1NCT03336580A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) AmyloidosisProthena Biosciences Limited · Amyloidogenic Transthyretin (ATTR) AmyloidosisTerminatedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2018ActualPhase 2NCT02613182Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) AmyloidosisProthena Biosciences Ltd. · AL AmyloidosisTerminatedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2018ActualNo phase registeredNCT02574676Quality of Life (QOL) Registry for Patients With AL AmyloidosisProthena Biosciences Ltd. · AL AmyloidosisCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2018ActualPhase 2NCT02632786The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) AmyloidosisProthena Biosciences Ltd. · AL AmyloidosisCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2018ActualPhase 2NCT03154047Study in Subjects With Light Chain (AL) AmyloidosisProthena Biosciences Ltd. · AL AmyloidosisTerminatedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2016ActualPhase 1/Phase 2NCT01707264Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) AmyloidosisProthena Biosciences Ltd. · Primary AmyloidosisCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2018ActualPhase 1NCT02630901Multiple Ascending Dose Study of PRX003 in Subjects With PsoriasisProthena Biosciences Limited · PsoriasisCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 1NCT02157714Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's DiseaseProthena Biosciences Limited · Parkinson's DiseaseCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2016ActualPhase 1NCT02458677Single Ascending Dose Study of PRX003 in Healthy SubjectsProthena Biosciences Limited · PsoriasisCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1NCT02095171Single Ascending Dose Study of PRX002 in Healthy SubjectsProthena Biosciences Limited · Parkinson's DiseaseCompletedPRTALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimatePhase 3NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseHoffmann-La Roche · Parkinson's DiseaseRecruitingPRTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 27, 2019ActualPhase 2NCT03100149A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseaseHoffmann-La Roche · Parkinson's DiseaseActive, not recruitingPRTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2024ActualPhase 2NCT04777331A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseHoffmann-La Roche · Parkinsons DiseaseActive, not recruitingPRTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2018ActualNo phase registeredNCT03043768Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's DiseaseGWT-TUD GmbH · Parkinson's DiseaseCompletedPRTACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner